FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1911089380> ?p ?o ?g. }

• W1911089380 endingPage "1788" @default.
• W1911089380 startingPage "1782" @default.
• W1911089380 abstract "Objective: Evaluate the safety and tolerability of beloranib, a fumagillin‐class methionine aminopetidase‐2 (MetAP2) inhibitor, in obese women over 4 weeks. Design and Methods: Thirty‐one obese (mean BMI 38 kg/m 2 ) women were randomized to intravenous 0.1, 0.3, or 0.9 mg/m 2 beloranib or placebo twice weekly for 4 weeks ( N = 7, 6, 9, and 9). Results: The most frequent AEs were headache, infusion site injury, nausea, and diarrhea. Nausea and infusion site injury occurred more with beloranib than placebo. The most common reason for discontinuation was loss of venous access. There were no clinically significant abnormal laboratory findings. In subjects completing 4 weeks, median weight loss with 0.9 mg/m 2 beloranib was −3.8 kg (95% CI −5.1, −0.9; N = 8) versus −0.6 kg with placebo (−4.5, −0.1; N = 6). Weight change for 0.1 and 0.3 mg/m 2 beloranib was similar to placebo. Beloranib (0.9 mg/m 2 ) was associated with a significant 42 and 18% reduction in triglycerides and LDL‐cholesterol, as well as improvement in C‐reactive protein and reduced sense of hunger. Changes in β‐hydroxybutyrate, adiponectin, leptin, and fibroblast growth factor‐21 were consistent with the putative mechanism of MetAP2 inhibition. Glucose and blood pressure were unchanged. Conclusions: Beloranib treatment was well tolerated and associated with rapid weight loss and improvements in lipids, C‐reactive protein, and adiponectin." @default.
• W1911089380 created "2016-06-24" @default.
• W1911089380 creator A5021649243 @default.
• W1911089380 creator A5043560888 @default.
• W1911089380 creator A5046558354 @default.
• W1911089380 creator A5054751943 @default.
• W1911089380 creator A5055583882 @default.
• W1911089380 creator A5061359578 @default.
• W1911089380 date "2013-05-25" @default.
• W1911089380 modified "2023-10-06" @default.
• W1911089380 title "Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women" @default.
• W1911089380 cites W1974550903 @default.
• W1911089380 cites W1977870045 @default.
• W1911089380 cites W1983150723 @default.
• W1911089380 cites W1991778481 @default.
• W1911089380 cites W1992860556 @default.
• W1911089380 cites W1999239339 @default.
• W1911089380 cites W2028904367 @default.
• W1911089380 cites W2031889037 @default.
• W1911089380 cites W2046859247 @default.
• W1911089380 cites W2050070442 @default.
• W1911089380 cites W2053380373 @default.
• W1911089380 cites W2053575156 @default.
• W1911089380 cites W2058533641 @default.
• W1911089380 cites W2062707154 @default.
• W1911089380 cites W2098387318 @default.
• W1911089380 cites W2107257265 @default.
• W1911089380 cites W2116226868 @default.
• W1911089380 cites W2134362869 @default.
• W1911089380 cites W2148287957 @default.
• W1911089380 cites W2152423343 @default.
• W1911089380 cites W2167222546 @default.
• W1911089380 doi "https://doi.org/10.1002/oby.20356" @default.
• W1911089380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23512440" @default.
• W1911089380 hasPublicationYear "2013" @default.
• W1911089380 type Work @default.
• W1911089380 sameAs 1911089380 @default.
• W1911089380 citedByCount "57" @default.
• W1911089380 countsByYear W19110893802014 @default.
• W1911089380 countsByYear W19110893802015 @default.
• W1911089380 countsByYear W19110893802016 @default.
• W1911089380 countsByYear W19110893802017 @default.
• W1911089380 countsByYear W19110893802018 @default.
• W1911089380 countsByYear W19110893802019 @default.
• W1911089380 countsByYear W19110893802020 @default.
• W1911089380 countsByYear W19110893802021 @default.
• W1911089380 countsByYear W19110893802022 @default.
• W1911089380 countsByYear W19110893802023 @default.
• W1911089380 crossrefType "journal-article" @default.
• W1911089380 hasAuthorship W1911089380A5021649243 @default.
• W1911089380 hasAuthorship W1911089380A5043560888 @default.
• W1911089380 hasAuthorship W1911089380A5046558354 @default.
• W1911089380 hasAuthorship W1911089380A5054751943 @default.
• W1911089380 hasAuthorship W1911089380A5055583882 @default.
• W1911089380 hasAuthorship W1911089380A5061359578 @default.
• W1911089380 hasConcept C126322002 @default.
• W1911089380 hasConcept C134018914 @default.
• W1911089380 hasConcept C142724271 @default.
• W1911089380 hasConcept C197934379 @default.
• W1911089380 hasConcept C204787440 @default.
• W1911089380 hasConcept C27081682 @default.
• W1911089380 hasConcept C2776782570 @default.
• W1911089380 hasConcept C2777391703 @default.
• W1911089380 hasConcept C2778375690 @default.
• W1911089380 hasConcept C2778715236 @default.
• W1911089380 hasConcept C2780580376 @default.
• W1911089380 hasConcept C511355011 @default.
• W1911089380 hasConcept C544821477 @default.
• W1911089380 hasConcept C71924100 @default.
• W1911089380 hasConcept C90924648 @default.
• W1911089380 hasConceptScore W1911089380C126322002 @default.
• W1911089380 hasConceptScore W1911089380C134018914 @default.
• W1911089380 hasConceptScore W1911089380C142724271 @default.
• W1911089380 hasConceptScore W1911089380C197934379 @default.
• W1911089380 hasConceptScore W1911089380C204787440 @default.
• W1911089380 hasConceptScore W1911089380C27081682 @default.
• W1911089380 hasConceptScore W1911089380C2776782570 @default.
• W1911089380 hasConceptScore W1911089380C2777391703 @default.
• W1911089380 hasConceptScore W1911089380C2778375690 @default.
• W1911089380 hasConceptScore W1911089380C2778715236 @default.
• W1911089380 hasConceptScore W1911089380C2780580376 @default.
• W1911089380 hasConceptScore W1911089380C511355011 @default.
• W1911089380 hasConceptScore W1911089380C544821477 @default.
• W1911089380 hasConceptScore W1911089380C71924100 @default.
• W1911089380 hasConceptScore W1911089380C90924648 @default.
• W1911089380 hasIssue "9" @default.
• W1911089380 hasLocation W19110893801 @default.
• W1911089380 hasLocation W19110893802 @default.
• W1911089380 hasOpenAccess W1911089380 @default.
• W1911089380 hasPrimaryLocation W19110893801 @default.
• W1911089380 hasRelatedWork W1990197915 @default.
• W1911089380 hasRelatedWork W2087016115 @default.
• W1911089380 hasRelatedWork W2112254863 @default.
• W1911089380 hasRelatedWork W2305775430 @default.
• W1911089380 hasRelatedWork W2360693916 @default.
• W1911089380 hasRelatedWork W2415484199 @default.
• W1911089380 hasRelatedWork W2465571689 @default.
• W1911089380 hasRelatedWork W3191427281 @default.

• next